Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
Authors:
- Laura C. CoatesLCLaura C. Coates
- Irene E. van der Horst-BruinsmaIHIrene E. van der Horst-Bruinsma
- Ennio LubranoEnnio Lubrano
- Steph BeaverSBSteph Beaver
- Emma DraneEDEmma Drane
- Baran UfuktepeBUBaran Ufuktepe
- Alexis R. OgdieAOAlexis R. Ogdie
- 15 October 2022
- journal article
- review article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (4) , 488-496
Abstract
We previously reported a novel E3 ubiquitin ligase (E3), designated as c-MIR, which targets B7-2 to lysosomal degradation and down-regulates the B7-2 surface expression through ubiquitination of its cytoplasmic tail. B7-2 is well known as a costimulatory molecule for Ag presentation, suggesting that the manipulation of c-MIR expression modulates immune responses in vivo. To examine this hypothesis, we generated genetically modified mice in which c-MIR was expressed under an invariant chain (Ii) promoter. Dendritic cells derived from genetically engineered mice showed low ability to present Ags. In addition, these mice showed resistance to the onset of experimental autoimmune encephalomyelitis and an impaired development of CD4 T cells in the thymus and the periphery. These findings led us to conclude that MHC class II (MHC II) is an additional target for c-MIR. Indeed, forced expression of c-MIR in several B cell lines down-regulated the surface expression of MHC II, and down-regulation was found to depend on the presence of a single lysine residue in the cytoplasmic tail of the I-A β-chain. In a reconstitution system using 293T cells, we found that the lysine residue at position 225 in the I-A β-chain was ubiquitinated by c-MIR. To our knowledge, c-MIR is the first example of an E3 that is capable of inhibiting MHC II expression. Our findings suggest that c-MIR might potently regulate immune responses in vivo.Keywords
This publication has 37 references indexed in Scilit:
- Comorbidities Associated with Psoriatic Arthritis Compared with Non-psoriatic Spondyloarthritis: A Cross-sectional StudyThe Journal of Rheumatology, 2015
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)Annals of the Rheumatic Diseases, 2014
- High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnairesAnnals of the Rheumatic Diseases, 2013
- Brief Report: Testosterone Is Protective in the Sexually Dimorphic Development of Arthritis and Lung Disease in SKG MiceArthritis & Rheumatism, 2013
- Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational studyBMC Medicine, 2012
- Sex Differences in Response to Anti-Tumor Necrosis Factor Therapy in Early and Established Rheumatoid Arthritis — Results from the DANBIO RegistryThe Journal of Rheumatology, 2011
- Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ‐II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)Arthritis Care & Research, 2011
- Sex differences in rheumatoid arthritis: more than meets the eye...BMC Medicine, 2009
- Psoriatic arthritis: epidemiology, clinical features, course, and outcomeAnnals of the Rheumatic Diseases, 2005
- Significance of the Stigmatization Experience of Psoriasis Patients: A 1-Year Follow-up of the Illness and its Psychosocial Consequences in Men and WomenActa Dermato-Venereologica, 2005